ArticleScience translational medicine2022

Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression.

Chengqiong Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.